中東およびアフリカの遺伝子治療市場 – 2030 年までの業界動向と予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

中東およびアフリカの遺伝子治療市場 – 2030 年までの業界動向と予測

  • Pharmaceutical
  • Published Report
  • Apr 2023
  • MEA
  • 350 ページ
  • テーブル数: 34
  • 図の数: 35

中東およびアフリカの遺伝子治療市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2024 –2030
Diagram 市場規模(基準年)
USD MILLION
Diagram Market Size (Forecast Year)
USD 1,019.11
Diagram CAGR
%
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>中東およびアフリカの遺伝子治療市場、ベクタータイプ別(ウイルスベクターおよび非ウイルスベクター)、方法別(体外および生体内)、用途別(腫瘍性疾患、心血管疾患、感染症、希少疾患、神経疾患、およびその他の疾患)、エンドユーザー別(がん研究所、病院、研究機関、その他) - 2030年までの業界動向および予測。

中東およびアフリカの遺伝子治療市場

中東およびアフリカの遺伝子治療市場の分析と洞察

中東およびアフリカの遺伝子治療市場は、市場プレーヤーの増加と高度なサービスおよび製品の利用可能性により、予測年度に成長すると予想されています。これに伴い、メーカーは市場に新しい製品を投入するための研究開発活動に取り組んでいます。

中東およびアフリカの遺伝子治療市場中東およびアフリカの遺伝子治療市場

遺伝子治療とその技術および開発に関する研究の増加により、市場の成長がさらに促進されると予想されます。ただし、この方法を実行する際の倫理的および安全性の懸念により、予測期間中の中東およびアフリカの遺伝子治療市場の成長が妨げられると予想されます。遺伝子工学およびヘルスケアにおける新興の先進分野である遺伝子治療の需要の増加により、市場に治療および診断アプローチを強化する機会がもたらされると予想されます。

 がんや遺伝性疾患に対するより質の高い医療への需要の高まりが、市場の成長を後押しすると予想されます。しかし、診断コストの高さと熟練した資格のある専門家の不足が、市場の成長を阻むと予想されます。

データブリッジマーケットリサーチは、中東およびアフリカの遺伝子治療市場は、予測期間中に16.6%のCAGRで成長し、2030年までに10億1,911万米ドルに達すると予測しています。診断および治療におけるエキソソーム研究製品の使用が増加しているため、製品は市場で最大のタイプセグメントを占めています。

レポートメトリック

詳細

予測期間

2023年から2030年

基準年

2022

歴史的な年

2021 (2015~2020年にカスタマイズ可能)

定量単位

売上高は百万米ドル、価格は米ドル

対象セグメント

ベクターの種類(ウイルスベクターと非ウイルスベクター)、方法(体外および体内)、用途(腫瘍性疾患、心血管疾患、感染症、希少疾患、神経疾患、その他の疾患)、エンドユーザー(がん研究所、病院、研究機関など)別

対象国

南アフリカおよびその他の中東およびアフリカ

対象となる市場プレーヤー

Novartis AG、Kite Pharma(Gilead Sciences, Inc.の子会社)、uniQure NV、Oxford Biomedica、Spark Therapeutics, Inc.、SIBONO、bluebird bio, Inc.、Shanghai Sunway Biotech Co., Ltd.、Biogen、Dendreon Pharmaceuticals LLC.、Amgen Inc.、AnGes, Inc.、Enzyvant Therapeutics GmbHなど

中東およびアフリカの遺伝子治療市場の定義

Gene therapy is a medical strategy that addresses the underlying genetic issue in order to treat or prevent disease. Instead of utilising drugs or surgery, gene therapy procedures allow doctors to treat a problem by changing a person's genetic composition. A select few disorders, including an eye condition called Leber congenital amaurosis and a muscle condition called spinal muscular atrophy, are being treated with gene therapy. To ensure that they will be secure and efficient, many other gene therapies are undergoing study. Medical professionals aim to soon apply the promising technique of genome editing to cure human illnesses.

The ability to successfully transport a therapeutic gene to a target cell is the most important prerequisite for gene therapy to be successful. Once transported, that gene must go to the cell wall's nucleus, where it will serve as a model for making protein molecules. The principal therapeutic action is then produced by the protein. For instance, cell destruction might be used in the treatment of tumours, whereas cell preservation might be used in the case of neurodegenerative illness. However, strict regulations and standards for the approval and commercialization of products is expected to restrain the market growth.

Middle East and Africa Gene Therapy Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • Novel approaches of gene therapy

Gene therapy has brought permanent cures for ailments that were previously simply temporary treatments. For a very long period, gene therapy did not work; however, in recent years, effective and long-lasting treated cases have been recorded. For a wide range of hereditary illnesses, including blood abnormalities, immunological deficiencies, vision issues, nerve cell regeneration, metabolic disorders, and different types of cancer, promising outcomes have been attained.

With more specificity and fewer side effects, gene therapy has the potential to be a customized medicine that can "cure" a variety of diseases. Gene therapy generally refers to the transfer of genetic material to treat an illness, or at the very least, to enhance a patient's clinical condition. Using viruses as genetic vectors to deliver the desired gene to the target cells is one method of how gene therapy functions. These vectors are classified as RNA-based or DNA-based viral vectors depending on the type of genome they contain.

The majority of experts concur that gene therapy has the potential to be the most intriguing use of DNA research to date. A simple intravenous injection of a gene transfer agent may one day be used to administer genes as medicine, seeking out target cells for stable, site-specific chromosomal integration and subsequent gene expression. It is predicted that there would be a need for gene therapy using revolutionary techniques that are being tested by researchers around the world and incorporated into conventional treatment is expected to act as driver for the growth of Middle East and Africa gene therapy market

  • Increasing prevalance of genetic disorders

A sizable share of prenatal and neonatal mortality in several nations in the Region is caused by genetic and congenital diseases. Many multifactorial ailments are often caused by genetic factors as well. Gene alterations that are essentially present in every cell in the body cause many hereditary diseases. These illnesses thus frequently impact many bodily systems, and the majority cannot be treated.

For instance,

  • The Department of Health indicated that roughly six out of ten people will be impacted by an ailment that has some genetic ties, according to the Government of Western Australia. Genetic disorders can range from minor to very severe. Between 3 and 5% of newborns born in Western Australia have genetic disorders or birth abnormalities

Mutations, exposure to chemicals and radiation, among other things, can all result in genetic disorders. Although some ailments have been treated with gene therapy, the majority of treatment plans for genetic disorders do not change the underlying genetic abnormality. For this, the prevalence of genetic abnormalities is significantly rising across all age groups and practically all geographic areas are expected to act as a driver for the growth of Middle East and Africa gene therapy market.

Restraint

  • High cost of gene therapy

A new line of medical treatments called gene therapy involves replacing, deleting, or introducing genetic information into a patient's genome in order to treat a condition. Even though it is still in its infancy, gene therapy has already shown tremendous promise for the treatment and even cure of once-intractable illnesses. Gene therapy pricing is still highly uncontrolled and determined on a case-by-case basis in many nations, frequently focusing on a single upfront payment.

For instance,

  • According to a news article published in Web MD in February 2023, Hemgenix is breaking records but is hardly an anomaly. In September 2022, Skysona, a medication for a rare neurological condition, went on sale for $3 million. Just one month prior, Zynteglo, a gene treatment for a genetic blood condition, made its market debut for $2.8 million. A cure for the genetic condition spinal muscular atrophy, which kills infants and young children, called Zolgensma cost $2.1 million in 2019.

Even if they are not always fully curative, gene therapies can be really transforming. The main barrier to accessing gene therapy is cost. The treatment landscape for many rare genetic illnesses will undergo significant change as additional gene therapy products become available, providing patients with potentially curative alternatives for the first time. The difficulty of making sure that all patients, not just a small group with financial means and privileged access to technology, may benefit from these cutting-edge therapies must be addressed by healthcare systems around the world. However, due to the high cost of the treatments

Opportunity

  • Rise in strategic acquisition and partnership among organizations

Recently, different organizations are stepping forward for partnership and collaboration to develop various gene therapy products that are essential for detecting genetic disorders. Not only this, with the help of partnerships and agreements both the companies can develop a new suite of technologies and platforms that will help to detect diseases.

With the help of a long-term agreement, both companies can provide dimensional pricing of gene therapy products in response to consumer demand in the market. Such partnership and mutual agreement not only benefit both the companies but are also creating a lot of opportunities for the market to grow.

For instance,

  • In July 2022, Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+

Therefore, a rise in collaboration & partnerships is further expected to create a lot of opportunities for the market to grow

Challenge

  • Stringent regulations for gene therapy products

The use of gene therapy across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases which are preventable by early diagnosis and timely treatments. At the same time, the players of the gene therapy in the market have to follow certain regulations to get approval from the upper authorities for the launching of the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. The pre-market approval of various gene therapy products varies from one country to another.

For instance,

  • In 2022, according to the information provided by Food and Drug Administration (FDA), the Center for Biologics Evaluation and Research (CBER) regulates cellular therapy products, human gene therapy products, and certain devices related to cell and gene therapy. CBER uses both the Public Health Service Act and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight.

Hence, stringent regulations for gene therapy products is different for different countries which is expected to act as a challenge in the market growth.

Recent Developments

  • In December 2022 Kite Pharma, Inc., and Daiichi Sankyo Co., Ltd. announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma. Only patients who have not previously had a transfusion of CAR T cells directed against the CD19 antigen should be treated with Yescarta
  • In December, Ferring Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved Adstiladrin (nadofaragene firadenovec-vncg), a novel adenovirus vector-based gene therapy, for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. This has helped the company to expand their product portfolio

Middle East and Africa Gene Therapy Market Scope

The Middle East and Africa gene therapy market is segmented into four notable segments based on vector type, method, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY VECTOR TYPE

  • Viral Vector
  • Non-Viral Vector

On the basis of vector type, the Middle East and Africa gene therapy market is segmented into viral and non-viral vector.

BY METHOD

  • Ex-Vivo
  • In-Vivo

On the basis of method, the Middle East and Africa gene therapy market is segmented into ex vivo and in vivo.

BY APPLICATION

  • Oncological Disorders
  • Cardiovascular Diseases
  • Infectious Disease
  • Rare Diseases
  • Neurological Disorders
  • Other Diseases

On the basis of application, the Middle East and Africa gene therapy market is segmented into oncological disorders, cardiovascular diseases, infectious diseases, rare diseases, neurological disorders, and other diseases.

BY END USER

  • Cancer Institutes
  • Hospitals
  • Research Institutes
  • Others

On the basis of end user, the Middle East and Africa gene therapy market is segmented into cancer institutes, hospitals, research institutes, and others.

遺伝子治療市場

Middle East and Africa Gene Therapy Market Regional Analysis/Insights

The Middle East and Africa gene therapy market is segmented into four notable segments based on vector type, method, application, and end user.

The countries covered in this market report are South Africa and the rest of the Middle East and Africa.

South Africa is dominating due to the presence of key market players in the largest consumer market with high GDP.

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される重要な指標の一部です。また、中東およびアフリカのブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、および販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。

競争環境と中東およびアフリカの遺伝子治療市場シェア分析

中東およびアフリカの遺伝子治療市場の競争状況では、競合他社ごとに詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と幅、アプリケーションの優位性、製品タイプのライフライン曲線が含まれます。上記のデータ ポイントは、中東およびアフリカの遺伝子治療市場への会社の重点にのみ関連しています。

中東およびアフリカの遺伝子治療市場で活動している主要企業には、ノバルティスAG、カイトファーマ(ギリアド・サイエンシズの子会社)、ユニキュアNV、オックスフォード・バイオメディカ、スパーク・セラピューティクス、SIBONO、ブルーバード・バイオ、上海サンウェイ・バイオテック、バイオジェン、デンドレオン・ファーマシューティカルズLLC、アムジェン、アンジェス、エンジヴァント・セラピューティクスGmbH、オーデュボン・バイオサイエンスなどがあります。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER FIVE ANALYSIS

5 UPDATE ON GERMLINE GENE THERAPY

5.1 GERMLINE GENE THERAPY

6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, MO

6.1 DRIVERS

6.1.1 NOVEL APPROACHES TO GENE THERAPY

6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS

6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES

6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE

6.2 RESTRAINTS

6.2.1 HIGH COST OF GENE THERAPY

6.2.2 ETHICAL AND SAFETY CONCERNS

6.2.3 COMPLEXITY OF GENE THERAPY

6.3 OPPORTUNITIES

6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS

6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS

6.4 CHALLENGES

6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS

6.4.2 LONG-TERM SAFETY AND EFFICACY

7 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE

7.1 OVERVIEW

7.2 VIRAL VECTOR

7.2.1 ADENOVIRUS

7.2.2 RETROVIRUS

7.2.3 LENTIVIRUS

7.2.4 ADENO-ASSOCIATED VIRUS

7.2.5 VACCINIA VIRUS

7.2.6 HERPES SIMPLEX VIRUS

7.2.7 OTHERS

7.3 NON-VIRAL VECTOR

7.3.1 LIPOFECTION

7.3.2 INJECTION OF NAKED DNA

8 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD

8.1 OVERVIEW

8.2 EX-VIVO

8.3 IN-VIVO

9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 ONCOLOGICAL DISORDERS

9.3 CARDIOVASCULAR DISEASES

9.4 INFECTIOUS DISEASES

9.5 RARE DISEASES

9.6 NUEROLOGICAL DISORDERS

9.7 OTHER DISEASES

10 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER

10.1 OVERVIEW

10.2 CANCER INSTITUTES

10.3 HOSPITALS

10.4 RESEARCH INSTITUTES

10.5 OTHERS

11 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY REGION

11.1 MIDDLE EAST AND AFRICA

11.1.1 SOUTH AFRICA

11.1.2 REST OF MIDDLE EAST AND AFRICA

12 MIDDLE EAST & AFRICA GENE THERAPY MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

13 COMPANY PROFILES

13.1 BIOGEN

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 COMPANY SHARE ANALYSIS

13.1.4 SWOT ANALYSIS

13.1.5 PRODUCT PORTFOLIO

13.1.6 RECENT DEVELOPMENT

13.2 KITE PHARMA

13.2.1 COMPANY SNAPSHOT

13.2.2 REVENUE ANALYSIS

13.2.3 COMPANY SHARE ANALYSIS

13.2.4 SWOT ANALYSIS

13.2.5 PRODUCT PORTFOLIO

13.2.6 RECENT DEVELOPMENT

13.3 NOVARTIS AG

13.3.1 COMPANY SNAPSHOT

13.3.2 REVENUE ANALYSIS

13.3.3 COMPANY SHARE ANALYSIS

13.3.4 SWOT ANALYSIS

13.3.5 PRODUCT PORTFOLIO

13.3.6 RECENT DEVELOPMENTS

13.4 BRISTOL-MYERS SQUIBB COMPANY.

13.4.1 COMPANY SNAPSHOT

13.4.2 REVENUE ANALYSIS

13.4.3 COMPANY SHARE ANALYSIS

13.4.4 SWOT ANALYSIS

13.4.5 PRODUCT PORTFOLIO

13.4.6 RECENT DEVELOPMENT

13.5 OXFORD BIOMEDICA

13.5.1 COMPANY SNAPSHOT

13.5.2 REVENUE ANALYSIS

13.5.3 COMPANY SHARE ANALYSIS

13.5.4 SWOT ANALYSIS

13.5.5 PRODUCT PORTFOLIO

13.5.6 RECENT DEVELOPMENTS

13.6 AGC BIOLOGICS

13.6.1 COMPANY SNAPSHOT

13.6.2 PRODUCT PORTFOLIO

13.6.3 RECENT DEVELOPMENT

13.7 ANGES, INC

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENT

13.8 AMGEN INC.

13.8.1 COMPANY SNAPSHOT

13.8.2 REVENUE ANALYSIS

13.8.3 PRODUCT PORTFOLIO

13.8.4 RECENT DEVELOPMENT

13.9 BLUEBIRD BIO, INC.

13.9.1 COMPANY SNAPSHOT

13.9.2 PRODUCT PORTFOLIO

13.9.3 RECENT DEVELOPMENT

13.1 CHIESI FARMACEUTICI S.P.A

13.10.1 COMPANY SNAPSHOT

13.10.2 REVENUE ANALYSIS

13.10.3 PRODUCT PORTFOLIO

13.10.4 RECENT DEVELOPMENT

13.11 DENDREON PHARMACEUTICALS LLC

13.11.1 COMPANY SNAPSHOT

13.11.2 PRODUCT PORTFOLIO

13.11.3 RECENT DEVELOPMENT

13.12 ENZYVANT THERAPEUTICS GMBH

13.12.1 COMPANY SNAPSHOT

13.12.2 RODUCT PORTFOLIO

13.12.3 RECENT DEVELOPMENT

13.13 FERRING B.V.

13.13.1 COMPANY SNAPSHOT

13.13.2 PRODUCT PORTFOLIO

13.13.3 RECENT DEVELOPMENT

13.14 JANSSEN PHARMACEUTICALS, INC.

13.14.1 COMPANY SNAPSHOT

13.14.2 PRODUCT PORTFOLIO

13.14.3 RECENT DEVELOPMENT

13.15 MALLINCKRODT.

13.15.1 COMPANY SNAPSHOT

13.15.2 REVENUE ANALYSIS

13.15.3 PRODUCT PORTFOLIO

13.15.4 RECENT DEVELOPMENT

13.16 ORCHARD THERAPEUTICS PLC.

13.16.1 COMPANY SNAPSHOT

13.16.2 REVENUE ANALYSIS

13.16.3 PRODUCT PORTFOLIO

13.16.4 RECENT DEVELOPMENT

13.17 SHANGHAI SUNWAY BIOTECH CO., LTD.

13.17.1 COMPANY SNAPSHOT

13.17.2 PRODUCT PORTFOLIO

13.17.3 RECENT DEVELOPMENT

13.18 SIBONO

13.18.1 COMPANY SNAPSHOT

13.18.2 PRODUCT PORTFOLIO

13.18.3 RECENT DEVELOPMENT

13.19 SPARK THERAPEUTICS, INC.

13.19.1 COMPANY SNAPSHOT

13.19.2 PRODUCT PORTFOLIO

13.19.3 RECENT DEVELOPMENT

13.2 UNIQURE NV.

13.20.1 COMPANY SNAPSHOT

13.20.2 REVENUE ANALYSIS

13.20.3 PRODUCT PORTFOLIO

13.20.4 RECENT DEVELOPMENT

14 QUESTIONNAIRE

15 RELATED REPORTS

表のリスト

TABLE 1 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 28 SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)

TABLE 29 SOUTH AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)

TABLE 30 SOUTH AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)

TABLE 31 SOUTH AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)

TABLE 32 SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 33 SOUTH AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 34 REST OF MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)

図表一覧

FIGURE 1 MIDDLE EAST & AFRICA GENE THERAPY MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA GENE THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA GENE THERAPY MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA GENE THERAPY MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA GENE THERAPY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA GENE THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA GENE THERAPY MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 MIDDLE EAST & AFRICA GENE THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA GENE THERAPY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA GENE THERAPY MARKET: SEGMENTATION

FIGURE 11 THE INCREASING PREVALENCE OF GENETIC DISORDERS AND GROWING DEMAND FOR PERSONALIZED MEDICINE ARE EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET FROM 2023 TO 2030

FIGURE 12 THE VIRAL VECTOR SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET

FIGURE 14 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY VECTOR TYPE, 2022

FIGURE 15 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY VECTOR TYPE, 2023-2030 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY VECTOR TYPE, CAGR (2023-2030)

FIGURE 17 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY VECTOR TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY METHOD, 2022

FIGURE 19 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY METHOD, 2023-2030 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY METHOD, CAGR (2023-2030)

FIGURE 21 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY METHOD, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY APPLICATION, 2022

FIGURE 23 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 25 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY END USER, 2022

FIGURE 27 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY END USER, CAGR (2023-2030)

FIGURE 29 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: SNAPSHOT (2022)

FIGURE 31 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: BY COUNTRY (2022)

FIGURE 32 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: BY COUNTRY (2023 & 2030)

FIGURE 33 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: BY COUNTRY (2022 & 2030)

FIGURE 34 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: VECTOR TYPE (2023-2030)

FIGURE 35 MIDDLE EAST & AFRICA GENE THERAPY MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Middle East and Africa Gene Therapy Market is projected to grow at a CAGR of 16.6% during the forecast period by 2030.
The future market value of the Middle East and Africa Gene Therapy Market is expected to reach USD 1,019.11 million by 2030.
The major players in the Middle East and Africa Gene Therapy Market are Novartis AG, Kite Pharma (a subsidiary of Gilead Sciences, Inc.), uniQure NV., Oxford Biomedica, Spark Therapeutics, Inc.. SIBONO, bluebird bio, Inc., Shanghai Sunway Biotech Co., Ltd., etc.
The countries covered in the Middle East and Africa Gene Therapy Market are South Africa and Rest of Middle East and Africa.